Sucampo must live with Takeda as Amitiza arbitration fails to go its way
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals' loss of an arbitration decision relating to a key partnership for its main commercial product Amitiza (lubiprostone) means that, like it or not, it will have to continue working with existing North American licensee Takeda.